Navigation Links
Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
Date:4/15/2008

-Researchers Now Able to Detect a Single Cancer Cell Through In Vivo

Imaging-

HOPKINTON, Mass., April 15 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today introduced Bioware(R) Ultra cell lines, a range of ultra bright light producing tumor cell lines created specifically for in vivo imaging applications. Bioware Ultra cell lines are 10 to 100 times brighter than cell lines created using traditional methods, which allows researchers, for the first time ever, to detect a single cancer cell in an animal via non-invasive in vivo imaging.

Visualizing and tracking tumor progression in vivo is critical to better understanding how therapeutic treatments impact disease. In vivo imaging provides researchers with the ability to recognize tumor growth and behaviors at the cellular level within living animals. By tagging a tumor with the gene for luciferase, the same gene that allows a firefly to glow, the tumor can produce light that can be monitored using Caliper's highly sensitive IVIS imaging systems. As the disease progresses and reacts to specific compounds, researchers can measure tumor growth and evaluate the efficacy of compounds in real time. This ability to track disease progression in vivo offers a more conclusive understanding of how potential drugs will react in and impact humans.

Increasing the brightness of tumor producing cell lines significantly improves researchers' ability to monitor early tumor behavior and detect micrometastases sooner. Caliper's Bioware Ultra light producing cell lines incorporate the enhanced luc2 gene from Promega. The luc2 gene, an optimized version of luciferase for expression in mammalian cells, creates intensified visible light allowing more sensitive non-invasive detection of cells in vivo. Bioware Ultra cell lines offer the most sensitive way to non-invasively examine tumor cell growth in vivo, far exceeding the capabilities of previously available cell lines.

"The ability to detect and monitor a single cancerous cell in an animal model dramatically improves the ability to understand disease evolution from early stages and reaction to treatment options," said Mark Roskey, vice president, reagents and applied biology, Caliper Life Sciences. "Previously, oncology researchers needed to tag nearly 500 cells before a sufficient signal could be monitored using optical imaging. Bioware Ultra cell lines are the only line of cells available that offers the research community the level of sensitivity to detect a single cell further demonstrating Caliper's commitment to increasing the capabilities of pre-clinical, non-invasive in vivo imaging."

Caliper Life Sciences today launched seven Bioware Ultra cell lines covering a range of cancer models, including breast, colorectal, lung and prostate as well as lymphoma. Available immediately, the Bioware Ultra cell lines express on average 1000 photons/sec/cell. This intense brightness facilitates research efforts to measure tumor growth before tumors are palpable, study tumors from very early stages when a small number of cells is present and to detect micrometastatic events. Bioware Ultra cell lines are optimal for studying variety of xenograft models including orthotopic models in mice and are confirmed to be pathogen free. For additional information or to order Bioware Ultra cell lines, please visit: http://www.caliperls.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions.

Caliper and Bioware are registered trademarks of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
2. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
5. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
6. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
7. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
8. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
9. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
10. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
11. Helix BioPharma reports Q2 2008 highlights, financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 ... ... a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved ... interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):